Why Novavax, Inc. Could Be a Gold Mine for Growth Investors
If you had the misfortune to buy Novavax (NASDAQ: NVAX) stock in July 2015 and held on, around 90% of your investment would have been wiped out. Ouch. Even if you had bought the biotech stock at the beginning of 2017, you would be losing money.
With that context, the following statement might seem crazy: Novavax could be a gold mine for growth investors. But sometimes it's the craziest ideas that prove to be the most successful. Here's why the growth prospects for Novavax just might be much greater than many think.
Source: Fool.com
Sanofi S.A. ADR Aktie
Deutliche Buy-Präferenz bei Sanofi S.A. ADR ohne Sell-Einschätzungen.
Ein leicht positives Kursziel von 55 € für Sanofi S.A. ADR gegenüber dem aktuellen Kurs von 52.0 € wird gesehen.